Good Vita / The learning library

Linaclotide

A peptide that acts locally on intestinal guanylate cyclase-C receptors.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Approved medicines Human trials in product label Digestive health

Also discussed as: Linzess

What it is and how it works

Linaclotide activates guanylate cyclase-C on the intestinal surface. This signaling increases intestinal fluid secretion and transit. Its local action illustrates that peptide medicines do not all work through the same hormones or require the same route of administration.

Source for the mechanism context →

A closer look at the cited evidence

Human trials in product label

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
DailyMed — Linzess mechanism and clinical studies
Design
Controlled clinical studies summarized by indication in the label.
Who or what was studied
Defined constipation-related populations with age-specific criteria.
What was observed
Trials measured bowel-movement and symptom outcomes relevant to the labeled diagnoses.
Limits of interpretation
This is not evidence for treating every cause of abdominal pain or constipation. Pediatric criteria and warnings require the current label.
Read the cited study or assessment →

What the evidence means

Labeled studies assess constipation-related symptoms in defined patient groups.

Approval and regulatory context

Linzess has approved constipation-related indications; patient age and diagnosis affect the exact label criteria.

Safety and uncertainty

The label includes a pediatric dehydration boxed warning, diarrhea precautions, and a contraindication for known or suspected mechanical gastrointestinal obstruction.

What remains uncertain

Similar symptoms can have different causes, which this page cannot diagnose. A symptom outcome in an eligible trial population should not become a recommendation for an unassessed reader.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment